A Phase III Study That Will Evaluate The Safety And Efficacy Of The Study Drug A Reversible Dual Inhibitor That Selectively Targets Phosphoinositide 3-Kinase PI3K And Mammalian Target Of Rapamycin Mtor In Patients With HR+/HER2- Locally Advanced Or Metastatic Breast Cancer Who Have Progressed On Or After Treatment With A CDK 4/6 Inhibitor

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05501886

Study #:
STUDY00149846

Start Date:
Nov 19, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05501886

View Complete Trial Details & Eligibility at ClinicalTrials.gov